At least 70 human cases of highly pathogenic avian influenza (HPAI) A H5N1 (i.e., "bird flu") have been reported in the U.S. since 2024, primarily among individuals with exposure to dairy cattle or poultry. These cases, along with the rapid transmission of bird flu among U.S. wild bird, poultry, and cattle populations, warrant testing of available influenza A diagnostics for their ability to detect 2024 H5N1 strains. We previously tested 12 lateral flow assays (LFAs) and 5 point-of-care (POC) nucleic acid amplification tests (NAATs) with influenza A(H5N1) clade 2.3.4.4b (https://doi.org/10.1101/2025.04.15.25325613) as part of pandemic preparedness assessment. Here we expand the analysis by testing six additional FDA-cleared small footprint, sample-to-answer NAATs. The tests are anonymized pending authorization from each company.